<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03651206</url>
  </required_header>
  <id_info>
    <org_study_id>ENGOT-en8</org_study_id>
    <nct_id>NCT03651206</nct_id>
  </id_info>
  <brief_title>Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib</brief_title>
  <acronym>ROCSAN</acronym>
  <official_title>A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tesaro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carcinosarcomas (CS) (malignant mixed Müllerian tumors) are highly aggressive and rare tumors&#xD;
      with a worldwide annual incidence between 0.5-3.3 cases/100.000 women. Gynecological CS, i.e.&#xD;
      ovarian CS (OCS) and uterine CS (UCS), have a 5-year overall survival (OS) &lt; 10% and a poor&#xD;
      prognosis. After initial treatment (surgery +/- adjuvant radiotherapies +/- chemotherapies&#xD;
      (CT)), vast majority of patients relapsed and received diverse CT producing modest benefits,&#xD;
      and nearly all patients will die. After first line CT including platinum salt, monotherapy&#xD;
      (doxorubicin or paclitaxel) is frequently used for relapsed patients, but the response rate&#xD;
      (RR) is &lt;20%, progression-free survival (PFS) &lt;4 months, and OS &lt;1 year. In this unmet need&#xD;
      situation, a better knowledge of these aggressive neoplasms is essential to propose new&#xD;
      therapeutic options.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2020</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 2 :&#xD;
Arm A - Niraparib&#xD;
Arm B - Niraparib plus TSR-042&#xD;
Arm C - Chemotherapy drugs&#xD;
Peak the winner between the Arm A or the arm B&#xD;
Phase 3:&#xD;
Arm A: The best arm of the phase 2&#xD;
Arm B: Chemotherapy drugs</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate (RR) at 4 months</measure>
    <time_frame>4 months after the last patient included</time_frame>
    <description>RR is defined as the proportion of patients with a partial response or complete response 4 months after randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>1 year after the last patient included</time_frame>
    <description>OS is the time from the date of the randomization until death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>1 year after the last patient included</time_frame>
    <description>PFS is the time from randomization to the date of event defined as the first documented progression (RECIST 1.1) or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Subsequent Treatment (TTST)</measure>
    <time_frame>1 year after the last patient included</time_frame>
    <description>TTST is the time from the date of randomization to the earliest date of anti-cancer therapy start following study treatment discontinuation, or death by any cause in the absence of start of new anti-cancer therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival 2 (PFS2)</measure>
    <time_frame>1 year after the last patient included</time_frame>
    <description>PFS2 is the time from the date of randomization to the second objective disease progression, or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>1 year after the last patient included</time_frame>
    <description>ORR is the proportion of patients with a best response of Complete Response or Partial Response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 year after the last patient included</time_frame>
    <description>Assessed by CTCAE 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes (PROs)</measure>
    <time_frame>1 year after the last patient included</time_frame>
    <description>Assessed with questionnaires to be completed by patient and collected frequently during the study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Ovarian Carcinosarcoma</condition>
  <condition>Endometrial Carcinosarcoma</condition>
  <arm_group>
    <arm_group_label>Arm A - Niraparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Niraparib, 200 mg or 300 mg, daily dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - Niraparib + TSR-042 (Dostarlimab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Niraparib, 200 mg or 300 mg, daily dose&#xD;
TSR042, intravenous infusion on Day 1 of every 21-day cycle at 500 mg for the 4 first cycles, followed by 1,000 mg on Day 1 of every 42-day cycle thereafter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C - Chemotherapy drugs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapies (Standard of care)&#xD;
For Ovarian Cancer Patients Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Pegylated Liposomal Doxorubicin, 40 mg/m², Intravenous, every 28 days Topotecan, 4mg/m², Intravenous, Day 1, 8, 15 every 28 days&#xD;
For Endometrial Cancer Patients Doxorubicin, 60 mg/m², Intravenous, every 21 days Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Gemcitabine, 800 mg/m², Intravenous, Day 1, 8 every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niraparib</intervention_name>
    <description>PARP Inhibitor</description>
    <arm_group_label>Arm A - Niraparib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Niraparib + TSR-042 (Dostarlimab)</intervention_name>
    <description>Combination of 2 drugs, a PARP Inhibitor and an Anti-PD-1</description>
    <arm_group_label>Arm B - Niraparib + TSR-042 (Dostarlimab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy Drugs</intervention_name>
    <description>Chemotherapies given in standard of care</description>
    <arm_group_label>Arm C - Chemotherapy drugs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Progressive or recurrent uterine or ovarian carcinosarcoma (Malignant Mixed Mullerian&#xD;
             Tumor-MMMT).&#xD;
&#xD;
          2. The primary diagnosis must be histologically confirmed and central pathological review&#xD;
             of the initial tumor or biopsy at relapse will be done.&#xD;
&#xD;
          3. Mandatory tumor sample: Availability of tumor sample from a recently (not older than 3&#xD;
             months) obtained archival FFPE tumor tissue block or agreement for having a new tumor&#xD;
             biopsy if lesion amenable.&#xD;
&#xD;
          4. Progressive disease as defined by RECIST 1.1., within 12 months from last chemotherapy&#xD;
             cycle.&#xD;
&#xD;
          5. Failure after ≥1 prior platinum containing regimen, which may have been given in the&#xD;
             adjuvant setting.&#xD;
&#xD;
          6. Patient must have had 1 prior chemotherapeutic regimen for management of&#xD;
             carcinosarcoma that may have included chemotherapy, chemotherapy and radiotherapy,&#xD;
             and/or consolidation/maintenance therapy.&#xD;
&#xD;
          7. Patient must be free of active infection requiring antibiotics.&#xD;
&#xD;
          8. Any hormonal therapy directed at the malignant tumor must be discontinued at least one&#xD;
             week prior to beginning protocol chemotherapy; continuation of hormone replacement&#xD;
             therapy is permitted.&#xD;
&#xD;
          9. Patient must have ECOG Performance Status &lt;2.&#xD;
&#xD;
         10. Life expectancy of &gt; 2 months.&#xD;
&#xD;
         11. Adequate bone marrow function:&#xD;
&#xD;
               -  Platelet count greater than or equal to 100,000/mm3&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) greater than or equal to 1,500/mm3&#xD;
&#xD;
               -  Hemoglobin &gt; 9g/dL&#xD;
&#xD;
         12. Adequate hepatic and renal function:&#xD;
&#xD;
               -  Total bilirubin ≤1.5x Upper Limit of Normal (ULN) unless liver metastases are&#xD;
                  present, in which case they must be ≤3x ULN (≤2.0 in patients with known Gilberts&#xD;
                  syndrome OR direct bilirubin ≤ 1 x ULN)&#xD;
&#xD;
               -  Serum creatinine ≤1.5x upper limit of normal (ULN) or calculated creatinine&#xD;
                  clearance ≥ 60 mL/min using Cockcroft-Gault equation&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5x ULN&#xD;
                  unless liver metastases are present, in which case they must be ≤5x ULN&#xD;
&#xD;
               -  Alkaline phosphatase &lt; 2.5 times ULN&#xD;
&#xD;
               -  Serum albumin &gt; 3 g/dL&#xD;
&#xD;
         13. International normalized ratio (INR) or prothrombin time (PT) ≤1.5× ULN unless patient&#xD;
             is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is&#xD;
             within therapeutic range of intended use of anticoagulants. Activated partial&#xD;
             thromboplastin time (aPTT) ≤1.5× ULN unless patient is receiving anticoagulant therapy&#xD;
             as long as PT or PTT is within therapeutic range of intended use of anticoagulants.&#xD;
&#xD;
         14. Patient must have normal BP or adequately treated and controlled hypertension&#xD;
             (systolic BP≤140 mmHg and/or diastolic BP ≤90 mmHg)&#xD;
&#xD;
         15. Patient receiving corticosteroids may continue as long as their dose is stable and&#xD;
             ≤10mg/day (prednisone equivalent) for at least 4 weeks prior to initiating protocol&#xD;
             therapy.&#xD;
&#xD;
         16. Patient must agree to not donate blood during the study or for 90 days after the last&#xD;
             dose of study treatment.&#xD;
&#xD;
         17. Left ventricular ejection fraction (LVEF) &gt; Lower Limit of Normal (LLN) as assessed by&#xD;
             either multigated acquisition (MUGA) scan or echocardiogram (ECHO), for patients&#xD;
             planned to receive Anthracycline based therapy.&#xD;
&#xD;
         18. Patient has a negative urine or serum pregnancy test within 7 days prior to taking&#xD;
             study treatment if of childbearing potential and agrees to abstain from activities&#xD;
             that could result in pregnancy from screening through 180 days after the last dose of&#xD;
             study treatment or is of nonchildbearing potential.&#xD;
&#xD;
               -  Non-childbearing potential is defined as follows:&#xD;
&#xD;
                    -  ≥45 years of age and has not had menses for &gt;1 year&#xD;
&#xD;
                    -  Patients who have been amenorrhoeic for &lt;2 years without history of a&#xD;
                       hysterectomy and oophorectomy must have a follicle stimulating hormone value&#xD;
                       in the postmenopausal range upon screening evaluation&#xD;
&#xD;
                    -  Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation.&#xD;
                       Documented hysterectomy or oophorectomy must be confirmed with medical&#xD;
                       records of the actual procedure or confirmed by an ultrasound. Tubal&#xD;
                       ligation must be confirmed with medical records of the actual procedure.&#xD;
&#xD;
               -  For women of childbearing potential: the patient must be willing to use 2&#xD;
                  adequate barrier methods throughout the study, starting with the screening visit&#xD;
                  through 180 days after the last dose of study treatment. See Section 4.3. for a&#xD;
                  list of acceptable birth control methods. Information must be captured&#xD;
                  appropriately within the site's source documents. Note: Abstinence is acceptable&#xD;
                  if this is the established and preferred contraception for the patient.&#xD;
&#xD;
         19. Patient must agree to not breastfeed during the study and for 180 days after the last&#xD;
             dose of study treatment.&#xD;
&#xD;
         20. Patient able to take oral medications.&#xD;
&#xD;
         21. 21. Female aged ≥18 years at time of signing ICF.&#xD;
&#xD;
         22. Patient must have signed an approved informed consent.&#xD;
&#xD;
         23. For France only: patient affiliated to, or a beneficiary of, a social security&#xD;
             category.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Not enrolled in any interventional clinical trial (except to biological trials that&#xD;
             must be validated by the sponsor).&#xD;
&#xD;
          2. Prior treatment with niraparib or other PARPi therapy or PD1/PDL-1 inhibitors.&#xD;
&#xD;
          3. Patient has had investigational therapy, immunotherapy, chemotherapy or biological&#xD;
             therapy administered within 4 weeks or within a time interval less than at least 5&#xD;
             half-lives of the investigational agent, whichever is longer, prior to randomization.&#xD;
             Patient has had radiotherapy within 4 weeks prior to randomization.&#xD;
&#xD;
          4. Patient must not have had major surgery ≤ 3 weeks prior to initiating protocol therapy&#xD;
             and participant must have recovered from any surgical effect.&#xD;
&#xD;
          5. Previous treatment with the chemotherapy regimen selected as the control arm by the&#xD;
             investigator.&#xD;
&#xD;
               -  Prior therapy with paclitaxel given on a three-weekly regimen is permitted for&#xD;
                  patients receiving weekly Paclitaxel.&#xD;
&#xD;
               -  Prior treatment with weekly paclitaxel is permitted where this has been used as&#xD;
                  part of first line therapy and it is greater than 6 months since the last dose of&#xD;
                  weekly paclitaxel.&#xD;
&#xD;
               -  Prior weekly paclitaxel for relapsed disease is not permitted.&#xD;
&#xD;
          6. Patients who have received more than 3 prior cytotoxic chemotherapies for management&#xD;
             of uterine or ovarian carcinosarcoma.&#xD;
&#xD;
          7. Patients with persistent, clinically significant &gt; Grade 1 toxicity.&#xD;
&#xD;
          8. Patient has clinically significant cardiovascular disease (eg, significant cardiac&#xD;
             conduction abnormalities, uncontrolled hypertension, myocardial infarction,&#xD;
             uncontrolled cardiac arrhythmia or unstable angina &lt; 6 months to enrollment, NHYA&#xD;
             grade 2 or greater congestive heart failure, serious cardiac arrhythmia requiring&#xD;
             medication, Grade 2 or greater peripheral vascular disease, and history of&#xD;
             cerebrovascular accident within 6 months)&#xD;
&#xD;
          9. Patients with any other severe concurrent disease, which may increase the risk&#xD;
             associated with study participation or study drug administration and, in the judgment&#xD;
             of the investigator, would make the patient inappropriate for entry into this study,&#xD;
             including significant neurologic, psychiatric, infectious, hepatic, renal, or&#xD;
             gastrointestinal diseases or laboratory abnormality. Examples include, but are not&#xD;
             limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial&#xD;
             infarction, uncontrolled major seizure disorder, unstable spinal cord compression,&#xD;
             superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining&#xD;
             informed consent.&#xD;
&#xD;
         10. Symptoms or signs of gastrointestinal obstruction requiring parenteral nutrition or&#xD;
             hydration or any other gastro-intestinal disorders or abnormalities, including&#xD;
             difficulty swallowing, that would interfere with drug absorption.&#xD;
&#xD;
         11. Patient experienced ≥ Grade 3 immune-related AE with prior immunotherapy, with the&#xD;
             exception of non-clinically significant lab abnormalities&#xD;
&#xD;
         12. Participant has had radiation therapy encompassing &gt;20% of the bone marrow within 2&#xD;
             weeks prior to Day 1 of protocol therapy, or any radiation therapy within 1 week prior&#xD;
             to Day 1 of protocol therapy.&#xD;
&#xD;
         13. Patient has a diagnosis of immunodeficiency or has received systemic steroid therapy&#xD;
             or any other form of immunosuppressive therapy within 7 days prior to initiating&#xD;
             protocol therapy&#xD;
&#xD;
         14. Patient has a known history of human immunodeficiency virus (type 1 or 2 antibodies).&#xD;
&#xD;
         15. Patient has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg]&#xD;
             reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [qualitative]&#xD;
             is detected).&#xD;
&#xD;
         16. Patient has an active autoimmune disease that has required systemic treatment in the&#xD;
             past 2 years (ie, with use of disease-modifying agents, corticosteroids, or&#xD;
             immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic&#xD;
             corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is&#xD;
             not considered a form of systemic treatment.&#xD;
&#xD;
         17. Patient must not have a history of interstitial lung disease.&#xD;
&#xD;
         18. Patient has received a live vaccine within 14 days of initiating protocol therapy.&#xD;
&#xD;
         19. Patient must not have received a transfusion (platelets or red blood cells) ≤ 4 weeks&#xD;
             prior to initiating protocol therapy.&#xD;
&#xD;
         20. Patient must not have received colony stimulating factors (eg, granulocyte&#xD;
             colony-stimulating factor, granulocyte macrophage colony stimulating factor, or&#xD;
             recombinant erythropoietin) within 4 weeks prior initiating protocol therapy.&#xD;
&#xD;
         21. Patient has had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to&#xD;
             prior chemotherapy that persisted &gt; 4 weeks and was related to the most recent&#xD;
             treatment.&#xD;
&#xD;
         22. Patient must not have any known history of myelodysplastic syndrome (MDS) or acute&#xD;
             myeloid leukemia (AML)&#xD;
&#xD;
         23. Symptomatic CNS metastasis or leptomeningeal carcinomatosis.&#xD;
&#xD;
         24. Patients with a history of other invasive malignancies (any evidence of other&#xD;
             malignancy being present within the last 3 years) or with a concomitant invasive&#xD;
             malignancy, with the exception of non-melanoma skin cancer; patients are also&#xD;
             ineligible if their previous cancer treatment contraindicates this protocol therapy.&#xD;
&#xD;
         25. Known, uncontrolled hypersensitivity reactions or allergy to investigational drugs or&#xD;
             their excipients that contraindicates the subject's participation.&#xD;
&#xD;
         26. Any psychological, familial, sociological or geographical consideration potentially&#xD;
             hampering compliance with the study protocol and follow up schedule; those&#xD;
             considerations should be discussed with the patient before registration in the trial.&#xD;
&#xD;
         27. Patients under psychiatric care and patients admitted to a health or social&#xD;
             institution.&#xD;
&#xD;
         28. Patients deprived of their liberty by judicial or administrative decision.&#xD;
&#xD;
         29. Patients under a legal protection measure or unable to express their consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Isabelle RAY-COQUARD, Professor</last_name>
    <phone>+33184852020</phone>
    <email>apailhe@arcagy.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bénédicte VOTAN</last_name>
    <phone>+33184852020</phone>
    <email>apailhe@arcagy.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICO Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frédéric BIGOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elsa Kalbacher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Régional de Lutte contre le cancer - Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne FLOQUET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Florence Joly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marie Ange Mouret Reynier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Valérie CHEVALIER-EVAIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Isabelle Ray Coquard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Magali Provansal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Régional du Cancer de Montpellier (ICM Val d'Aurelle)</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michel Fabbro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé du Confluent S.A.S.</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alain Lortholary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nicolas Delanoy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier des Diaconesses Croix Saint-Simon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Frédéric Selle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>76016</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Audrey Bellesoeur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre CARIO-HPCA</name>
      <address>
        <city>Plérin</city>
        <zip>22190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne Claire Hardy Bessard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Milétrie - Centre Hospitalier Universitaire Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nadia Raban, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Claudia Lefeuvre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Saint Herblain</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dominique Berton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICANS</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lauriane EBERST, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Régaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laurence Gladieff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexandra Leary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malignant mixed Mullerian tumors</keyword>
  <keyword>Metastatic ovarian carcinosarcoma</keyword>
  <keyword>Recurrent ovarian carcinosarcoma</keyword>
  <keyword>Metastatic endometrial carcinosarcoma</keyword>
  <keyword>Recurrent endometrial carcinosarcoma</keyword>
  <keyword>Niraparib</keyword>
  <keyword>TSR-042 (Dostarlimab)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinosarcoma</mesh_term>
    <mesh_term>Mixed Tumor, Mullerian</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niraparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No sharing plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

